Syndax Medical Affairs / Information

Issa et al. J Clin Oncol. 2025 Jan;43(1):75-84. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

kmt2a; augment; monotherapy; AUGMENT-101; NCT04065399; relapsed; refractory; acute; leukemia; all; aml